Why the study?
Do fenofibrate and niacin alter intrahepatic triglyceride content, VLDL kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease?
Do fenofibrate and niacin alter intrahepatic triglyceride content, VLDL kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease?
Fenofibrate and niacin lower VLDL triglycerides through distinct mechanisms (increased clearance vs. decreased secretion) without affecting liver fat content in obese patients with NAFLD.
Fenofibrate or niacin can lower VLDL-TG in obese NAFLD without raising liver fat; extends evidence for their distinct kinetic actions.
Fenofibrate and Niaspan decrease plasma VLDL-TG concentration without altering IHTG content. However, the mechanism responsible for the change in VLDL-TG concentration is different for each drug; fenofibrate increases plasma VLDL-TG clearance, whereas nicotinic acid decreases VLDL-TG secretion.
No takes yet. Share an insight, caveat, or question.
Fabbrini et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: